Floatz logo

Datopotamab Deruxtecan

Additional Indications Below for Module 4 and 5

AstraZenecaantibody_drug_conjugatePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Additional Indications Below for Module 4 and 5 cohort.

Asset / SponsorPhaseRating
T-Dxd
AstraZeneca
Phase 1/2CCC
Carboplatin
AstraZeneca
Phase 1/2CCC
Camizestrant
AstraZeneca
Phase 1/2CCC
azd5305
AstraZeneca
Phase 1/2CCC

Same molecule, other indications

Datopotamab Deruxtecan is also rated in:

stomatitisDormant
BB
Indicative ·
65 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
63 / 100
View asset →
biliary tract cancerDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →